Hyaluronic Acid-decorated Redox-sensitive Chitosan Micelles for Tumor-specific Intracellular Delivery of Gambogic Acid

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2019 Jul 16

PMID 31303753

Citations 18

Authors

Wei Xu

Honglan Wang

Lihui Dong

Pan Zhang

Yan Mu

Xueyan Cui

Jianping Zhou

Meirong Huo

Tingjie Yin

Affiliations

Soon will be listed here.

Abstract

Herein, a hyaluronic acid (HA)-coated redox-sensitive chitosan-based nanoparticle, HA(HECS-ss-OA)/GA, was successfully developed for tumor-specific intracellular rapid delivery of gambogic acid (GA). The redox-sensitive polymer, HECS-ss-OA, was prepared through a well-controlled synthesis procedure with a satisfactory reproducibility and stable resulted surface properties of the assembled cationic micelles. GA was solubilized into the inner core of HECS-ss-OA micelles, while HA was employed to coat outside HECS-ss-OA/GA for CD44-mediated active targeting along with protection from cation-associated in vivo defects. The desirable redox-sensitivity of HA(HECS-ss-OA)/GA was demonstrated by morphology and particle size changes alongside in vitro drug release of nanoparticles in different simulated reducing environments. The results of flow cytometry and confocal microscopy confirmed the HA-receptor mediated cellular uptake and burst drug release in highly reducing cytosol of HA(HECS-ss-OA)/GA. Consequently, HA(HECS-ss-OA)/GA showed the highest apoptosis induction and cytotoxicity over the non-sensitive (HA(HECS-cc-OA)/GA) and HA un-coated (HECS-ss-OA/GA) controls against A549 NSCLC model both in vitro and in vivo. Furthermore, a diminished systemic cytotoxicity was observed in HA(HECS-ss-OA)/GA treated mice compared with those treated by HA un-coated cationic ones and GA solution.

Citing Articles

pH-Sensitive Fluorescent Marker Based on Rhodamine 6G Conjugate with Its FRET/PeT Pair in "Smart" Polymeric Micelles for Selective Imaging of Cancer Cells.

Zlotnikov I, Ezhov A, Kudryashova E Pharmaceutics. 2024; 16(8).

PMID: 39204352 PMC: 11360677. DOI: 10.3390/pharmaceutics16081007.

Targeted Polymeric Micelles System, Designed to Carry a Combined Cargo of L-Asparaginase and Doxorubicin, Shows Vast Improvement in Cytotoxic Efficacy.

Zlotnikov I, Kudryashova E Polymers (Basel). 2024; 16(15).

PMID: 39125158 PMC: 11314107. DOI: 10.3390/polym16152132.

Nanostructured lipid carriers loaded with morellic acid for enhanced anticancer efficacy: preparation, characterization, pharmacokinetics and anticancer evaluation.

Jia B, Li S, Li L, Wang T, Chen W, Chen G Am J Cancer Res. 2024; 14(3):1101-1120.

PMID: 38590403 PMC: 10998744. DOI: 10.62347/VBOX7111.

Specific FRET Probes Sensitive to Chitosan-Based Polymeric Micelles Formation, Drug-Loading, and Fine Structural Features.

Zlotnikov I, Savchenko I, Kudryashova E Polymers (Basel). 2024; 16(6).

PMID: 38543345 PMC: 10975940. DOI: 10.3390/polym16060739.

Emerging tendencies for the nano-delivery of gambogic acid: a promising approach in oncotherapy.

Fahmy S, Elghanam R, Rashid G, Youness R, Sedky N RSC Adv. 2024; 14(7):4666-4691.

PMID: 38318629 PMC: 10840092. DOI: 10.1039/d3ra08042k.

References

Luo Y, Prestwich G . Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug Chem. 1999; 10(5):755-63. DOI: 10.1021/bc9900338. View

Molina J, Yang P, Cassivi S, Schild S, Adjei A . Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008; 83(5):584-94. PMC: 2718421. DOI: 10.4065/83.5.584. View

Ito T, Koyama Y, Otsuka M . Analysis of the surface structure of DNA/polycation/hyaluronic acid ternary complex by Raman microscopy. J Pharm Biomed Anal. 2009; 51(1):268-72. DOI: 10.1016/j.jpba.2009.07.024. View

Zhu X, Zhang H, Lin Y, Chen P, Min J, Wang Z . Mechanisms of gambogic acid-induced apoptosis in non-small cell lung cancer cells in relation to transferrin receptors. J Chemother. 2010; 21(6):666-72. DOI: 10.1179/joc.2009.21.6.666. View

Li H, Huo M, Zhou J, Dai Y, Deng Y, Shi X . Enhanced oral absorption of paclitaxel in N-deoxycholic acid-N, O-hydroxyethyl chitosan micellar system. J Pharm Sci. 2010; 99(11):4543-53. DOI: 10.1002/jps.22159. View

Zhou C, Wu Y, Chen G, Feng J, Liu X, Wang C . Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12(8):735-42. DOI: 10.1016/S1470-2045(11)70184-X. View

Li J, Huo M, Wang J, Zhou J, Mohammad J, Zhang Y . Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. Biomaterials. 2011; 33(7):2310-20. DOI: 10.1016/j.biomaterials.2011.11.022. View

Wang X, Chen W . Gambogic acid is a novel anti-cancer agent that inhibits cell proliferation, angiogenesis and metastasis. Anticancer Agents Med Chem. 2012; 12(8):994-1000. DOI: 10.2174/187152012802650066. View

Hou L, Yao J, Zhou J, Zhang Q . Pharmacokinetics of a paclitaxel-loaded low molecular weight heparin-all-trans-retinoid acid conjugate ternary nanoparticulate drug delivery system. Biomaterials. 2012; 33(21):5431-40. DOI: 10.1016/j.biomaterials.2012.03.070. View

10.

Huo M, Zou A, Yao C, Zhang Y, Zhou J, Wang J . Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles. Biomaterials. 2012; 33(27):6393-407. DOI: 10.1016/j.biomaterials.2012.05.052. View

11.

Wang X, Deng R, Lu Y, Xu Q, Yan M, Ye D . Gambogic acid as a non-competitive inhibitor of ATP-binding cassette transporter B1 reverses the multidrug resistance of human epithelial cancers by promoting ATP-binding cassette transporter B1 protein degradation. Basic Clin Pharmacol Toxicol. 2012; 112(1):25-33. DOI: 10.1111/j.1742-7843.2012.00921.x. View

12.

Li C, Qi Q, Lu N, Dai Q, Li F, Wang X . Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells. Biochem Cell Biol. 2012; 90(6):718-30. DOI: 10.1139/o2012-030. View

13.

Chi Y, Zhan X, Yu H, Xie G, Wang Z, Xiao W . An open-labeled, randomized, multicenter phase IIa study of gambogic acid injection for advanced malignant tumors. Chin Med J (Engl). 2013; 126(9):1642-6. View

14.

Ramasamy T, Tran T, Choi J, Cho H, Kim J, Yong C . Layer-by-layer coated lipid-polymer hybrid nanoparticles designed for use in anticancer drug delivery. Carbohydr Polym. 2014; 102:653-61. DOI: 10.1016/j.carbpol.2013.11.009. View

15.

Shi S, Shi K, Tan L, Qu Y, Shen G, Chu B . The use of cationic MPEG-PCL-g-PEI micelles for co-delivery of Msurvivin T34A gene and doxorubicin. Biomaterials. 2014; 35(15):4536-47. DOI: 10.1016/j.biomaterials.2014.02.010. View

16.

Ishaq M, Khan M, Sharma K, Sharma G, Dutta R, Majumdar S . Gambogic acid induced oxidative stress dependent caspase activation regulates both apoptosis and autophagy by targeting various key molecules (NF-κB, Beclin-1, p62 and NBR1) in human bladder cancer cells. Biochim Biophys Acta. 2014; 1840(12):3374-84. DOI: 10.1016/j.bbagen.2014.08.019. View

17.

Huu V, Luo J, Zhu J, Zhu J, Patel S, Boone A . Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye. J Control Release. 2015; 200:71-7. PMC: 4384820. DOI: 10.1016/j.jconrel.2015.01.001. View

18.

Zhong Y, Zhang J, Cheng R, Deng C, Meng F, Xie F . Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts. J Control Release. 2015; 205:144-54. DOI: 10.1016/j.jconrel.2015.01.012. View

19.

Tabatabaei S, Girouard H, Carret A, Martel S . Remote control of the permeability of the blood-brain barrier by magnetic heating of nanoparticles: A proof of concept for brain drug delivery. J Control Release. 2015; 206:49-57. DOI: 10.1016/j.jconrel.2015.02.027. View

20.

Wang S, Wang L, Chen M, Wang Y . Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression. Chem Biol Interact. 2015; 235:76-84. DOI: 10.1016/j.cbi.2015.03.017. View